United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $548.96, for a total transaction of $5,215,120.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,240,016.48. The trade was a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
United Therapeutics Stock Performance
NASDAQ UTHR opened at $552.48 on Friday. The company has a market cap of $23.45 billion, a PE ratio of 20.39, a P/E/G ratio of 1.82 and a beta of 0.58. The firm’s 50 day moving average price is $557.18 and its 200-day moving average price is $529.32. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $6.63 EPS. On average, analysts forecast that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.
Hedge Funds Weigh In On United Therapeutics
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. Bank of America lifted their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Royal Bank Of Canada increased their target price on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $646.00.
View Our Latest Analysis on UTHR
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
